Loading
A phase 2 trial of Patient-derived organoids in Colorectal cancer, run by Oslo University Hospital, now recruiting.
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer is a phase 2 interventional study registered as NCT05725200 by Oslo University Hospital, with 40 participants planned, started 2022-09-27 and due to reach its primary completion in 2038-12-31. Interventions recorded: Alectinib, Cetuximab, Crizotinib, Dasatinib, Everolimus, Encorafenib, Gemcitabine, Idelalisib, Larotrectinib, Methotrexate, Palbociclib, Panobinostat, Pembrolizumab, Petrozumab, Trastuzumab, Talazoparib, Venetoclax. Conditions recorded: Metastatic Colorectal Cancer.
Linked to the technology Patient-derived organoids because the registry's title names it ("patient derived organoids") and Colorectal cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Panobinostat, Gemcitabine and the tag pipeline.
Shares Idelalisib, Venetoclax and the tag pipeline.
Shares Cetuximab, Pembrolizumab, Colorectal cancer and the tag pipeline.
Shares Panobinostat and the tag pipeline.
Shares Panobinostat and the tag pipeline.
Shares Everolimus, Palbociclib and the tag pipeline.
Shares Palbociclib, Cetuximab and the tag pipeline.
Shares Patient-derived organoids, Gemcitabine and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/